Hormonal contraception: Recent advances and controversies

Fertility and Sterility

Volumn 82, Issue 2, 2004, Pages 520-526

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DEPOT MEDROXYPROGESTERONE ACETATE; DESOGESTREL; DROSPIRENONE; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; ETYNODIOL DIACETATE; GESTODENE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MESTRANOL PLUS NORETYNODREL; MIFEPRISTONE; NANDROLONE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETHISTERONE ENANTATE; NORETYNODREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ACNE; AMENORRHEA; BLEEDING; BONE DISEASE; BREAST CARCINOMA; BREAST TENDERNESS; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTRACEPTIVE DEVICE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG TOLERABILITY; ECTOPIC PREGNANCY; EMERGENCY TREATMENT; ENDOMETRIUM CARCINOMA; HEADACHE; HEART INFARCTION; HIRSUTISM; HORMONAL CONTRACEPTION; HUMAN; LEUKORRHEA; MEDICAL DOCUMENTATION; META ANALYSIS; NAUSEA; OBESITY; ORAL CONTRACEPTION; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; UTERINE CERVIX CARCINOMA; VAGINITIS; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT GAIN;

EID: 4143051244     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2004.03.019     Document Type: Article

References (78)

1. Speroff L, Glass RH, Kase NG, eds. Clinical gynecologic endocrinology and infertility. Baltimore: 1999;867-945
2. Sang G.W., Shao Q.X., Ge R.S., Ge J.L., Chen J.K., Song S., et al. A multicentered phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given by intramuscular injection to Chinese women. II. The comparison of bleeding patterns. Contraception. 51:1995;185-192
3. Kaunitz A.M., Garceau R.J., Cromie M.A. Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group. Contraception. 60:1999;179-187
4. TM monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum® 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives. Contraception. 62:2000;289-295
5. Rahimy M.H., Ryan K.K. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) assessment of return of ovulation after three monthly injections in surgically sterile women. Contraception. 60:1999;189-200
6. Abrams L.S., Skee D., Natarajan J., Wong F.A. Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril. 77:(Suppl 2):2002;S3-12
7. Zieman M., Guillebaud J., Weisberg E., Shangold G.A., Fisher A.C., Creasy G.W. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system the analysis of pooled data. Fertil Steril. 77:(Suppl 2):2002;S13-18
8. Audet M.C., Moreau M., Koltun W.D., Waldbaum A.S., Shangold G., Fisher A.C. ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive a randomized controlled trial. JAMA. 285:2001;2347-2354
9. Mulders T.M., Dieben T.O. Use of novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril. 75:2001;865-870
10. Roumen F.J., Apter D., Mulders T.M., Dieben T.O. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol. Hum Reprod. 16:2001;469-475
11. Luukkainen T., Pakarinen P., Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med. 19:2001;355-363
12. Andersson K., Odlind V., Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use a randomized comparative trial. Contraception. 49:1994;56-72
13. Nilsson C.G. Comparative quantitation of menstrual blood loss with a d-norgestrel-releasing IUD and a Nova-T-copper device. Contraception. 15:1977;379-387
14. Hidalgo M., Bahamondes L., Perrotti M., Diaz J., Dantas-Monteiro C., Petta C. Bleeding patterns and clinical performance of the levonorgestrel- releasing intrauterine system (Mirena) up to two years. Contraception. 65:2002;129-132
15. Sivin I., Stern J., Diaz S., Pavez M., Alvarez F., Brache V., et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol. 166:1992;1208-1213
16. Sivin I., Campodonico I., Kiriwat O., Holma P., Diaz S., Wan L., et al. The performance of levonorgestrel rod and Norplant contraceptive implants a 5 year randomized study. Hum Reprod. 13:1998;3371-3378
17. Sivin I., Alvarez F., Mishell D.R. Jr, Darney P., Wan L., Brache V., et al. Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic. Contraception. 58:1998;275-282
18. Meckstroth K.R., Darney P.D. Implant contraception. Semin Reprod Med. 19:2001;339-354
19. Hammond G.L., Rabe T., Wagner J.D. Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy. Am J Obstet Gynecol. 185:2001;S24-31
20. Krattenmacher R. Drospirenone pharmacology and pharmacokinetics of a unique progestogen. Contraception. 62:2000;29-38
21. Poindexter A. The emerging use of the 20-microg oral contraceptive. Fertil Steril. 75:2001;457-465
22. Rosenberg M.J., Meyers A., Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception. 60:1999;321-329
23. Miller L., Notter K.M. Menstrual reduction with extended use of combination oral contraceptive pills randomized controlled trial. Obstet Gynecol. 98:2001;771-778
24. Kwiecien M., Edelman A., Nichols M.D., Jensen J.T. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive a randomized trial. Contraception. 67:2003;9-13
25. Piaggio G., von Hertzen H., Grimes D.A., Van Look P.F. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet. 353:1999;721
26. Trussell J., Rodriguez G., Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception. 57:1998;363-369
27. Trussell J., Rodriguez G., Ellertson C. Updated estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception. 59:1999;147-151
28. Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet. 352:1998;428-433
29. Raymond E.G., Creinin M.D., Barnhart K.T., Lovvorn A.E., Rountree R.W., Trussell J. Meclizine for prevention of nausea associated with use of emergency contraceptive pills a randomized trial. Obstet Gynecol. 95:2000;271-277
30. Nielsen C.L., Miller L. Ectopic gestation following emergency contraceptive pill administration. Contraception. 62:2000;275-276
31. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 25: emergency oral contraception. 2001;American College of Obstetricians and Gynecologists, Washington, DC
32. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1999;353:697-702
33. Ashok P.W., Stalder C., Wagaarachchi P.T., Flett G.M., Melvin L., Templeton A. A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. BJOG. 109:2002;553-560
34. Glasier A., Thong K.J., Dewar M., Mackie M., Baird D.T. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med. 327:1992;1041-1044
35. Ries L.A.G., Eisner M.P., Kosary C.L., Hankey B.F., Miller B.A., Clegg L., et al. SEER cancer statistics review, 1975-2000. 2003;National Cancer Institute, Bethesda, MD
36. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27
37. Schlesselman J.J., Collins J.A. The influence of steroids on gynecologic cancers. Fraser I.S., Jansen R.P.S., Lobo R.A., Whitehead M.I. Estrogens and progestogens in clinical practice. 1999;831-864 Churchill Livingston, London
38. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987;257:796-800
39. Weiderpass E., Adami H.O., Baron J.A., Magnusson C., Lindgren A., Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 10:1999;277-284
40. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer 1991;49:186-90
41. Schlesselman J.J. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol. 85:1995;793-801
42. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987;316:650-5
43. Schildkraut J.M., Calingaert B., Marchbanks P.A., Moorman P.G., Rodriguez G.C. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 94:2002;32-38
44. Narod S.A., Risch H., Moslehi R., Dorum A., Neuhausen S., Olsson H., et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditory Ovarian Cancer Clinical Study Group. N Engl J Med. 339:1998;424-428
45. Gross T.P., Schlesselman J.J. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol. 83:1994;419-424
46. Ylitalo N., Sorensen P., Josefsson A., Frisch M., Sparen P., Ponten J., et al. Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. Int J Cancer. 81:1999;357-365
47. Kjellberg L., Hallmans G., Ahren A.M., Johansson R., Bergman F., Wadell G., et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer. 82:2000;1332-1338
48. Salazar E.L., Sojo-Aranda I., Lopez R., Salcedo M. The evidence for an etiological relationship between oral contraceptive use and dysplastic change in cervical tissue. Gynecol Endocrinol. 15:2001;23-28
49. Moreno V., Bosch F.X., Munoz N., Meijer C.J., Shah K.V., Walboomers J.M., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection the IARC multicentric case-control study. Lancet. 359:2002;1085-1092
50. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:1999;12-19
51. Skegg D.C. Oral contraceptives, parity, and cervical cancer. Lancet. 359:2002;1080-1081
52. Munoz N., Franceschi S., Bosetti C., Moreno V., Herrero R., Smith J.S., et al. Role of parity and human papillomavirus in cervical cancer the IARC multicentric case-control study. Lancet. 359:2002;1093-1101
53. Fernandez E., La Vecchia C., Balducci A., Chatenoud L., Franceschi S., Negri E. Oral contraceptives and colorectal cancer risk a meta-analysis. Br J Cancer. 84:2001;722-727
54. Cundy T., Cornish J., Roberts H., Elder H., Reid I.R. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol. 92:1998;569-573
55. Petitti D.B., Piaggio G., Mehta S., Cravioto M.C., Meirik O. Steroid hormone contraception and bone mineral density a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol. 95:2000;736-744
56. Berenson A.B., Radecki C.M., Grady J.J., Rickert V.I., Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 98:2001;576-582
57. American College of Obstetricians and Gynecologists. ACOG committee revises recommendations on OCs with third-generation progestins. ACOG Today 1998;July
58. Cundy T., Cornish J., Evans M.C., Roberts H., Reid I.R. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ. 308:1994;247-248
59. Orr-Walker B.J., Evans M.C., Ames R.W., Clearwater J.M., Cundy T., Reid I.R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol. 49:1998;615-618
60. Cromer B.A., Blair J.M., Mahan J.D., Zibners L., Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 129:1996;671-676
61. Naessen T., Olsson S.E., Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception. 52:1995;35-39
62. Horowitz M., Wishart J.M., Need A.G., Morris H.A., Nordin B.E. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis. Clin Endocrinol. 39:1993;649-655
63. Kleerekoper M., Brienza R.S., Schultz L.R., Johnson C.C. Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group. Arch Intern Med. 151:1991;1971-1976
64. Michaelsson K., Baron J.A., Farahmand B.Y., Persson I., Ljunghall S. Oral-contraceptive use and risk of hip fracture a case-control study. Lancet. 353:1999;1481-1484
65. Perrotti M., Bahamondes L., Petta C., Castro S. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. Fertil Steril. 76:2001;469-473
66. Farley T.M., Meirik O., Collins J. Cardiovascular disease and combined oral contraceptives reviewing the evidence and balancing the risks. Hum Reprod Update. 5:1999;721-735
67. Tanis B.C., van den Bosch M.A., Kemmeren J.M., Cats V.M., Helmerhorst F.M., Algra A., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 345:2001;1787-1793
68. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997;349:1202-9
69. Kemmeren J.M., Tanis B.C., van den Bosch M.A., Bollen E.L., Helmerhorst F.M., van der Graaf Y., et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study oral contraceptives and the risk of ischemic stroke. Stroke. 33:2002;1202-1208
70. Chang C.L., Donaghy M., Poulter N. Migraine and stroke in young women case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ. 318:1999;13-18
71. Curtis K.M., Chrisman C.E., Peterson H.B. WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances. Obstet Gynecol. 99:2002;1100-1112
72. Gerstman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., Lundin F.E. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 133:1991;32-37
73. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8
74. Kemmeren J.M., Algra A., Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis meta-analysis. BMJ. 323:2001;131-134
75. Pymar H.C., Creinin M.D. The risks of oral contraceptive pills. Semin Reprod Med. 19:2001;305-312
76. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 344:1994;1453-1457
77. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W., Middeldorp S., Helmerhorst F.M., Bouma B.N., et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 344:2001;1527-1535
78. Martinelli I., Taioli E., Bucciarelli P., Akhavan S., Mannucci P.M. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol. 19:1999;700-703